5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice

5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice

Salvage chemotherapy for patients with unresectable pancreatic cancer (UR-PC) who have been treated with gemcitabine and nab-paclitaxel (GnP), and 5-fluorouracil (5-FU)/l-leucovorin (LV) plus nanoliposomal irinotecan (nal-IRI), has not been fully established. We retrospectively reviewed data from 17...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Takuo Yamai, Kenji Ikezawa, Yasuharu Kawamoto, Takeru Hirao, Sena Higashi, Kazuma Daiku, Shingo Maeda, Yutaro Abe, Makiko Urabe, Yugo Kai, Ryoji Takada, Tasuku Nakabori, Hiroyuki Uehara, Kazuyoshi Ohkawa
Định dạng: Bài viết
Ngôn ngữ:English
Được phát hành: MDPI AG 2022-04-01
Loạt:Current Oncology
Những chủ đề:
pancreatic cancer
FOLFOX
chemotherapy
Truy cập trực tuyến:https://www.mdpi.com/1718-7729/29/4/216

Internet

https://www.mdpi.com/1718-7729/29/4/216

Những quyển sách tương tự